Journal
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
Volume 97, Issue 9, Pages 3893-3900Publisher
SPRINGER
DOI: 10.1007/s00253-012-4682-z
Keywords
Bioengineered heparin; High cell density cultivations; Heparosan; Sulfotransferase
Categories
Funding
- National Institutes of Health [HL096972]
- Bioengineered Heparin Consortium
- USA-Italy Fulbright Commission
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL096972] Funding Source: NIH RePORTER
Ask authors/readers for more resources
A bioengineered heparin, as a replacement for animal-derived heparin, is under development that relies on the fermentative production of heparosan by Escherichia coli K5 and its subsequent chemoenzymatic modification using biosynthetic enzymes. A critical enzyme in this pathway is the mammalian 6-O-sulfotransferase (6-OST-1) which specifically sulfonates the glucosamine residue in a heparin precursor. This mammalian enzyme, previously cloned and expressed in E. coli, is required in kilogram amounts if an industrial process for bioengineered heparin is to be established. In this study, high cell density cultivation techniques were exploited to obtain recombinant 6-OST-1. Physiological studies were performed in shake flasks to establish optimized growth and production conditions. Induction strategies were tested in fed-batch experiments to improve yield and productivity. High cell density cultivation in 7-l culture, together with a coupled inducer strategy using isopropyl beta-d-1-thiogalactopyranoside and galactose, afforded 482 mg l(-1) of enzyme with a biomass yield of 16.2 mg g(cdw) (-1) and a productivity of 10.5 mg l(-1) h(-1).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available